{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:47:36Z","timestamp":1761238056422,"version":"3.44.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1517\/14728214.2014.872628","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T06:32:30Z","timestamp":1389162750000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Emerging drugs for bipolar depression: an update"],"prefix":"10.1517","volume":"19","author":[{"given":"Paul A","family":"Keedwell","sequence":"first","affiliation":[{"name":"Neuroscience and Mental Health Research Institute","place":["UK"]},{"name":"Institute of Psychiatry, Kings College London, Centre for Affective Disorders","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Kings College London, Centre for Affective Disorders","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.5.543"},{"key":"e_1_3_1_4_1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1176\/appi.ajp.2010.09071011","article-title":"Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication","volume":"167","author":"Angst J","year":"2010","unstructured":"Angst J, Cui L, Swendsen J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010;167:1194-201","journal-title":"Am J Psychiatry"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.05.011"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00909-4"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20521"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01324.x"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322234"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.12.004"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.03.003"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80070-4"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.06.016"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.10.002"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.11.008"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1203"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.09.009"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12025"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04995gre"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m06878"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00344.x"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00368.x"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.4.392"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048504"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04152"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-153"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-198910000-00006"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199812000-00003"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.02.018"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000171519.64080.c9"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.01.024"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04942gre"},{"key":"e_1_3_1_33_1","first-page":"121","article-title":"Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review","volume":"45","author":"Harel EV","year":"2008","unstructured":"Harel EV, Levkovitz Y. Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review. Isr J Psychiatry Relat Sci 2008;45:121-8","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.04200030104017"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790220086014"},{"key":"e_1_3_1_36_1","first-page":"1097","article-title":"NIMH report. Five-center study clarifies use of lithium, imipramine for recurrent affective disorders","volume":"35","author":"Prien RF","year":"1984","unstructured":"Prien RF. NIMH report. Five-center study clarifies use of lithium, imipramine for recurrent affective disorders. Hosp Community Psychiatry 1984;35:1097-8","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_3_1_37_1","first-page":"981","article-title":"Long-term maintenance drug therapy in recurrent affective illness: current status and issues","volume":"38","author":"Prien RF","year":"1977","unstructured":"Prien RF, Caffey EM Jr. Long-term maintenance drug therapy in recurrent affective illness: current status and issues. Dis Nerv Syst 1977;38:981-92","journal-title":"Dis Nerv Syst"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.232"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-5618.2003.00083.x"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2001.00383.x"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2001.30505.x"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.105.013045"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13020185"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000248603.76231.b7"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/2194-7511-1-10"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.337"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0811"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.041301"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.00997.x"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/00124509-199803000-00006"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.660146"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028725"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04301"},{"key":"e_1_3_1_57_1","unstructured":"Takeda. Efficacy and safety of ramelteon sublingual in adult patients with acute depressive episodes associated with bipolar I disorder. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01467700 [Last accessed 18 November 2013]"},{"key":"e_1_3_1_58_1","unstructured":"Takeda. Safety and efficacy study of ramelteon (TAK-375) tablets for sublingual administration (SL) in adults with bipolar 1 disorder. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01677182 [Last accessed 19 August 2013]"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.01.047"},{"key":"e_1_3_1_60_1","unstructured":"Johnson & Johnson Pharmaceutical Research & Development LLC. Evaluation of effectiveness and safety of flexible-dose paliperidone extended release in patients with schizoaffective disorder. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00412373 [Last accessed 18 May 2011]"},{"key":"e_1_3_1_61_1","unstructured":"Forest Laboratories. Safety tolerability and efficacy of cariprazine for patients with bipolar depression. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01396447 [Last accessed 19 November 2013]"},{"key":"e_1_3_1_62_1","unstructured":"Laboratories F. Safety and efficacy of RGH-188 (Cariprazine) in bipolar depression. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00852202 [Last accessed 25 February 2009]"},{"key":"e_1_3_1_63_1","unstructured":"Otsuka Pharmaceutical Development & Commercialization I. A study of aripiprazole in patients with bipolar I disorder with a major depressive episode. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00338273 [Last accessed 7 November 2013]"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.03.013"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.564"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-15872"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000612"},{"key":"e_1_3_1_68_1","unstructured":"Sheba Medical Center. A placebo controlled trial of the dopamine D-2 receptor agonist ropinirole in treatment of 60 patients with refractory bipolar depression. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00335205 [Last accessed 8 June 2006]"},{"key":"e_1_3_1_69_1","unstructured":"Teva Pharmaceutical Industries (Cephalon). Study to evaluate the efficacy and safety of armodafinil treatment as adjunctive therapy in adults with major depression associated with bipolar I disorder. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01072630 [Last accessed 20 March 2013]"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12020219"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.246"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.09.005"},{"key":"e_1_3_1_73_1","unstructured":"Pfizer. Study evaluating bifeprunox in bipolar depression. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00134459 [Last accessed 12 February 2013]"},{"key":"e_1_3_1_74_1","unstructured":"GlaxoSmithKline. Safety tolerability and pharmacokinetics of repeat doses of GSK1014802. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00908154 [Last accessed May 29 2009]"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.11.023"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14728214.2014.872628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:31:59Z","timestamp":1756719119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14728214.2014.872628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1517\/14728214.2014.872628"],"URL":"https:\/\/doi.org\/10.1517\/14728214.2014.872628","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"type":"print","value":"1472-8214"},{"type":"electronic","value":"1744-7623"}],"subject":[],"published":{"date-parts":[[2014,1,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}